Back to mobile site

Piper Jaffray Sees Value in Allergen (AGN) Post-Pfizer; PT to $311

April 6, 2016 11:29 AM EDT Send to a Friend
Piper Jaffray analyst David Amsellem reiterated his Overweight rating while trimming his price target on Allergen (NYSE: AGN) to $311.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login